A Study of ALPN-303 in Adult Healthy Volunteers (RUBY-1)

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Placebo; Drug: ALPN-303

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Brisbane, Queensland, Australia, 4006
      • Investigative Site
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Summary of Inclusion Criteria:

• Able and willing to provide written informed consent
• Body mass index 18 to 32 kg/m2
• Agree to avoid strenuous physical activity for 2 days prior to each study visit
• Agree to use highly effective contraception during the study (all participants) and for 90 days after study drug dosing (males) or for 60 days after study drug dosing (females)
• Male participants must refrain from donating sperm during the study and for 90 days after study drug dosing
• Female participants must not be pregnant or breastfeeding and must refrain from donating ova during the study and for 60 days after study drug dosing
• Must have completed vaccination against SARS-CoV-2 at least 4 weeks prior to study drug dosing

Summary of Exclusion Criteria:

• Any current disease, condition, or treatment that could interfere with the study, interfere with interpretation of the data, or pose an unacceptable risk to the participant
• History or symptoms of significant psychiatric disease; mild, resolved depression or anxiety is acceptable
• History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency; see protocol for clarifications/exceptions
• History of significant hepatic or renal disease or impairment
• Evidence of an active or suspected cancer or a history of malignancy within the previous 3 years; see protocol for exceptions
• History of major organ transplantation with an existing functional graft
• Use or receipt of prescription medications, over-the-counter medications, herbal remedies, or investigation products (study drugs) within protocol-defined timeframes prior to study entry; hormone replacement therapy initiated at least 2 months prior to Screening is acceptable
• Significant loss of blood or blood product (including donation) over 500 mL or transfusion of any blood product during Screening or within 3 months of Screening
• Unwilling to refrain from alcohol use ≥ 48 hours prior to Study Day -1.
• Known hypersensitivity, allergy, or intolerance to ALPN-303, Fc-based biologic therapy, or any of the excipients contained in the ALPN-303 formulation
• Immunization with any live vaccine within 6 weeks prior to study drug administration, or expected to require any live vaccines during the study or within 6 weeks after receiving study drug
• Acceptable laboratory assessments at Screening and Day -1
• Positive screen for drugs of abuse or alcohol at Screening or Day -1
• Positive tests for infectious disease (HIV, hepatitis B, hepatitis C, SARS-CoV-2)
• Acute infection during or within 4 weeks prior to Screening
• History of frequent or atypical infections as defined per protocol; signs or symptoms of immunodeficiency
• History or presence of any chronic infectious condition
• Cardiac risk factors, as defined per protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ALPN-303 Regimen A	Drug: ALPN-303; Multiple dose levels will be evaluated.
Placebo Comparator: Placebo Regimen A	Drug: Placebo; Placebo will be administered
Experimental: ALPN-303 Regimen B	Drug: ALPN-303; Multiple dose levels will be evaluated.
Placebo Comparator: Placebo Regimen B	Drug: Placebo; Placebo will be administered

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent Adverse Events (TEAE)	Type, incidence, and severity of TEAE as assessed by CTCAE	Day 1 through Day 30

Collaborators and Investigators

• Sponsor: Alpine Immune Sciences, Inc.
• Investigators: Study Director: Stanford Peng, MD PhD, Alpine Immune Sciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2021
• Primary Completion (Actual): February 27, 2023
• Study Completion (Actual): February 27, 2023

Study Registration Dates

• First Submitted: August 26, 2021
• First Submitted That Met QC Criteria: August 30, 2021
• First Posted (Actual): September 5, 2021

Study Record Updates

• Last Update Posted (Actual): May 9, 2023
• Last Update Submitted That Met QC Criteria: May 5, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Healthy Volunteer; BAFF; APRIL
• Other Study ID Numbers: AIS-D01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No